Hemolytic uremic syndrome following prolonged gemcitabine therapy:: report of four cases from a single institution

被引：51

作者：

Müller, S ^{[1
]}

Schütt, P ^{[1
]}

Bojko, P ^{[1
]}

Nowrousian, MR ^{[1
]}

Hense, J ^{[1
]}

Seeber, S ^{[1
]}

Moritz, T ^{[1
]}

机构：

[1] Univ Duisburg Essen, Sch Med, W German Canc Ctr, Dept Internal Med Canc Res, D-45122 Essen, Germany

来源：

ANNALS OF HEMATOLOGY | 2005年 / 84卷 / 02期

关键词：

hemolytic uremic syndrome; hemolysis; gemcitabine; thrombocytopenia; renal failure; microangiopathic thrombotic disease;

D O I：

10.1007/s00277-004-0938-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently, several cases of gemcitabine-induced HUS have been observed with the overall incidence of gemcitabine-induced HUS estimated at 0.015-0.25%. We here report on four patients who developed HUS following gemcitabine therapy at our institution within the last year (incidence 1.4%). All these patients had advanced-stage disease, were heavily pretreated, and received prolonged gemcitabine application, suggesting that in this subgroup of patients HUS may be more frequently encountered than documented so far.

引用

页码：110 / 114

页数：5

共 25 条

[1] Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias [J].